Indeed, an inverse correlation between miR-320 and β-catenin expressions has been monitored in CD44+ PCa cells, thus suggesting that miR-320 may inhibit Wnt/β-catenin-mediated downstream effects on CSC pathophysiology in prostate cancer [70]. The gene discussed is CD44; the disease is prostate carcinoma.